Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cerevel Therapeutics Hldg Inc
(NQ:
CERE
)
44.96
UNCHANGED
Last Price
Updated: 4:15 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cerevel Therapeutics Hldg Inc
< Previous
1
2
3
4
5
6
Next >
Cerevel Therapeutics Hldg: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
April 10, 2023
Via
Benzinga
Where Cerevel Therapeutics Hldg Stands With Analysts
April 03, 2023
Via
Benzinga
Analyst Expectations for Cerevel Therapeutics Hldg's Future
March 09, 2023
Via
Benzinga
Data Shows Cerevel's Emraclidine Does Not Induce High Blood Pressure In Schizophrenia Patients
December 19, 2022
Via
Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
December 06, 2022
Via
Benzinga
Analyst Ratings for Cerevel Therapeutics Hldg
September 13, 2022
Analysts have provided the following ratings for Cerevel Therapeutics Hldg (NASDAQ:CERE) within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
March 17, 2023
Via
Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
August 23, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
February 23, 2023
Via
Benzinga
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 22, 2023
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous...
Via
Benzinga
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
Madrigal Pharmaceuticals, Cerevel Therapeutics And Some Other Big Stocks Moving Higher On Monday
December 19, 2022
U.S. stocks traded mixed, with the Nasdaq Composite dropping around 90 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
November 09, 2022
Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%
November 09, 2022
B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from $73 to $61. Tyson Foods shares fell 1.9% to $66.44 in pre-market trading.
Via
Benzinga
Why Cerevel Therapeutics Holdings Shares Are Nosediving
November 08, 2022
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 6.42% to $25.37 during Tuesday's session after the company reported worse-than-expected third-quarter EPS results and filed...
Via
Benzinga
What 8 Analyst Ratings Have To Say About Cerevel Therapeutics Hldg
October 20, 2022
Cerevel Therapeutics Hldg (NASDAQ:CERE) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
October 20, 2022
Upgrades
Via
Benzinga
Analyst Ratings for Cerevel Therapeutics Hldg
September 29, 2022
Over the past 3 months, 8 analysts have published their opinion on Cerevel Therapeutics Hldg (NASDAQ:CERE) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022
September 26, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
September 13, 2022
Upgrades See all analyst ratings upgrades.
Via
Benzinga
Cerevel Therapeutics Shares Are Falling: Here's Why
August 16, 2022
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 7.1% to $32.00 during Tuesday's trading session. The company on Friday priced its underwritten common stock offering of 7.25...
Via
Benzinga
Bumble, Hanesbrands, Sonos And Some Other Big Losers From Thursday
August 12, 2022
U.S. stocks closed mixed on Thursday following the release of PPI data. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
August 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Via
Benzinga
Here's Why Cerevel Therapeutics Stock Is Getting Hammered Today
August 11, 2022
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower after the company announced a proposed public offering of $250 million of common stock.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.